174 related articles for article (PubMed ID: 8599963)
1. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
Grünwald F; Schomburg A; Bender H; Klemm E; Menzel C; Bultmann T; Palmedo H; Ruhlmann J; Kozak B; Biersack HJ
Eur J Nucl Med; 1996 Mar; 23(3):312-9. PubMed ID: 8599963
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Eur J Nucl Med; 1997 Nov; 24(11):1342-8. PubMed ID: 9371865
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Grünwald F; Menzel C; Bender H; Palmedo H; Willkomm P; Ruhlmann J; Franckson T; Biersack HJ
Thyroid; 1997 Jun; 7(3):327-35. PubMed ID: 9226199
[TBL] [Abstract][Full Text] [Related]
4. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG-PET in the follow-up of thyroid cancer.
Lind P; Kresnik E; Kumnig G; Gallowitsch HJ; Igerc I; Matschnig S; Gomez I
Acta Med Austriaca; 2003; 30(1):17-21. PubMed ID: 12558561
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
7. Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
Hsu CH; Liu RS; Wu CH; Chen SM; Shih LS
J Formos Med Assoc; 2002 Jul; 101(7):459-67. PubMed ID: 12353337
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.
Grünwald F; Kälicke T; Feine U; Lietzenmayer R; Scheidhauer K; Dietlein M; Schober O; Lerch H; Brandt-Mainz K; Burchert W; Hiltermann G; Cremerius U; Biersack HJ
Eur J Nucl Med; 1999 Dec; 26(12):1547-52. PubMed ID: 10638405
[TBL] [Abstract][Full Text] [Related]
9. Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose.
Caleo O; Maurea S; Klain M; Salvatore B; Storto G; Mancini M; Pace L; Salvatore M
Radiol Med; 2008 Mar; 113(2):278-88. PubMed ID: 18386128
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
[TBL] [Abstract][Full Text] [Related]
11. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
12. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
[TBL] [Abstract][Full Text] [Related]
13. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results.
Stokkel MP; de Klerk JH; Zelissen PM; Koppeschaar HP; van Rijk PP
Eur J Nucl Med; 1999 Dec; 26(12):1606-9. PubMed ID: 10638413
[TBL] [Abstract][Full Text] [Related]
17. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
18. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
19. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
20. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
